Exploratory biomarker findings from regorafenib plus toripalimab in patients with refractory metastatic colorectal cancer (REGOTORI study).

Gastroenterol Rep (Oxf) · 2026 · PMC12944821 · PMID 41767624

Europe PMC DOI

hedged sentences

0.0630

closest p · 1.3× alpha

0.0750

boldest claim

The sentences

borderline significanceP = 0.063so close (0.05 < p ≤ 0.1)

This difference was supported by a log-rank test ( P = 0.043), although the Cox model showed only borderline significance ( P = 0.063; Fig. 2B ).

also in 7,017 other papers

showed a trendP = 0.075so close (0.05 < p ≤ 0.1)

5B ), and also showed a trend toward improved OS (NR vs 10.3 months; HR = 4.03, 95% CI: 0.78–20.91; P = 0.075; Fig. 5C ).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

Although this did not reach statistical significance, the direction and magnitude of the association suggest that tissue- and blood-based heterogeneity might be biologically connected and should be validated in larger cohorts.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.